Otonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa

Back to Jobs

SAN DIEGO , June 09, 2016 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the enrollment of the first patient in the single OTIPRIO TM

Apply Now